• Beta Bionics Chief Commercial Officer Mark Hopman sold 370 shares of common stock on Nov. 2, 2026, at $16.9 each.
• His direct ownership totaled 54,143 shares following the sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002048497-26-000025), on November 04, 2026, and is solely responsible for the information contained therein.